Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Craig A. Portell, MD, N. Nora Bennani, MD, Opeyemi Jegede, PhD, Seema Naik, MD, Benjamin M Parsons, DO, Priyank P Patel, MD, Christopher M. Reynolds, MD, Brad S. Kahl, MD

Blood (2019) 134 (Supplement_1): 5243.

https://doi.org/10.1182/blood-2019-122759

Published: 2019

Journal Articles

Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)

Cory Mavis, BSc, MSc, Pallawi Torka, MD, Alison Zeccola, Priyank P. Patel, MD, Juan Gu, MD PhD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 1542.

https://doi.org/10.1182/blood.V130.Suppl_1.1542.1542

Published: 2017

Journal Articles

Pre-Clinical Investigation of Targeted Therapies for Double Hit Diffuse Large B-Cell Lymphoma (DH-DLBCL)

Priyank P. Patel, MD, Alison Zeccola, Vishala T. Neppalli, MD, Juan J Gu, PhD, Cory Mavis, MSc, Sheila Sait, PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 5122.

https://doi.org/10.1182/blood.V126.23.5122.5122

Published: 2015

Journal Articles

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Pallawi Torka, MD, Priyank P. Patel, MD, Wei Tan, Gregory Wilding, Seema A. Bhat, MD, Myron S. Czuczman, MD, Kelvin P. Lee, MD, George Deeb, MD, Vishala T. Neppalli, MD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 3975.

https://doi.org/10.1182/blood.V126.23.3975.3975

Published: 2015

Journal Articles

Intense Cytarabine-Based Chemo-Immunotherapy, Central Nervous System (CNS) Prophylaxis and Early High-Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS) in First Remission Are Associated with an Improved Clinical Outcome in Double-Hit (DHL)/Triple-Hit (THL) Diffuse Large B-Cell Lymphoma (DLBCL)

Priyank P. Patel, MD, Pallawi Torka, MD, Vishala T. Neppalli, MD, George Deeb, MD, Sheila N.J. Sait, PhD, AnneMarie W. Block, PhD, Seema A. Bhat, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2014) 124 (21): 3031.

https://doi.org/10.1182/blood.V124.21.3031.3031

Published: 2014

NARROW

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)

Pre-Clinical Investigation of Targeted Therapies for Double Hit Diffuse Large B-Cell Lymphoma (DH-DLBCL)

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study

Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)

Pre-Clinical Investigation of Targeted Therapies for Double Hit Diffuse Large B-Cell Lymphoma (DH-DLBCL)

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only